人表皮生长因子受体2(HER2)阳性早期乳腺癌(BC)降阶梯策略:西德研究组ADAPT试验最终分析——优化早期BC风险评价与治疗反应预测的辅助动态标志物调整的个体化治疗II期随机试验——12周疗效、安全性与预测标志物
ADAPT试验为前瞻性新辅助II期随机试验,375例HER2阳性/HR阳性早期乳腺癌患者随机接受12周T-DM1±内分泌治疗(ET)或曲妥珠单抗+ET。T-DM1组和T-DM1+ET组的病理完全缓解(pCR)率分别为41.0%和41.5%,均高于曲妥珠单抗+ET组的15.1%(P<.001)。早期应答者pCR率35.7%,非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。
要点
- 12周T-DM1±ET的pCR率分别为41.0%和41.5%,曲妥珠单抗+ET为15.1%(P<.001)。
- 早期应答者pCR率35.7%,非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。
- T-DM1组1-2级毒性(血小板减少、恶心、肝酶升高)更常见,严重不良事件T-DM1组5.3% vs 曲妥珠单抗+ET组3.1%。
核心结论
- 新辅助T-DM1(联合或不联合ET)仅12周即可获得有临床意义的pCR率,使相当数量患者免于全身化疗的不良反应。
研究设计与样本
- 前瞻性新辅助II期随机试验(ADAPT),筛查463例,随机分配375例HER2阳性/HR阳性早期乳腺癌患者。
- 患者随机接受12周T-DM1±ET或曲妥珠单抗+ET,主要终点为pCR(ypT0/is/ypN0),通过3周治疗后核心穿刺活检评估早期应答(Ki-67增殖下降≥30%或细胞密度应答)。
主要发现
- T-DM1组pCR率41.0%,T-DM1+ET组41.5%,曲妥珠单抗+ET组15.1%(P<.001)。
- 早期应答者(占可评估应答患者的67%)pCR率35.7%,非应答者19.8%(OR 2.2,95%CI 1.24-4.19)。
- T-DM1组1-2级毒性(尤其是血小板减少、恶心和肝酶升高)发生率显著更高;总体毒性较低,治疗相关严重不良事件共17例,T-DM1组5.3% vs 曲妥珠单抗+ET组3.1%。
关键数值与推荐
- 早期应答定义为3周治疗后核心穿刺活检Ki-67增殖下降≥30%或细胞密度应答。
- pCR定义为ypT0/is/ypN0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Human epidermal growth factor receptor 2 (HER2)-positive/hormone receptor (HR)-positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little is known about the efficacy of the combination of endocrine therapy (ET) with trastuzumab or with the potent antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1) with or without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzumab with ET in early HER2-positive/HR-positive breast cancer. Patients and Methods In this prospective, neoadjuvant, phase II trial, 375 patients with early breast cancer with HER2-positive and HR-positive status (n = 463 screened) were randomly assigned to 12 weeks of T-DM1 with or without ET or to trastuzumab with ET. The primary end point was pCR (ypT0/is/ypN0). Early response was assessed in 3-week post-therapeutic core biopsies (proliferation decrease ≥ 30% Ki-67 or cellularity response). Secondary end points included safety and predictive impact of early response on pCR. Adjuvant therapy followed national standards. Results Baseline characteristics were well balanced among the arms. More than 90% of patients completed the therapy per protocol. pCR was observed in 41.0% of patients treated with T-DM1, 41.5% of patients treated with T-DM1 and ET, and 15.1% with trastuzumab and ET ( P < .001). Early responders (67% of patients with assessable response) achieved pCR in 35.7% compared with 19.8% in nonresponders (odds ratio, 2.2; 95% CI, 1.24 to 4.19). T-DM1 was associated with a significantly higher prevalence of grade 1 to 2 toxicities, especially thrombocytopenia, nausea, and elevation of liver enzymes. Overall toxicity was low; seventeen therapy-related severe adverse events (T-DM1 arms v trastuzumab plus ET; 5.3% v 3.1%, respectively) were reported. Conclusion The ADAPT HER2-positive/HR-positive trial demonstrates that neoadjuvant T-DM1 (with or without ET) given for only 12 weeks results in a clinically meaningful pCR rate. Thus, a substantial number of patients are spared the adverse effects of systemic chemotherapy.
引用
- Harbeck N, Gluz O, Christgen M, et al. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin Oncol. 2017. PMID: 28682681. doi:10.1200/JCO.2016.71.9815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。